352 Index Name Paper ref. Name Paper ref. Merino, D Wed 087 Merkord, J Thu 337 Merlin, J Wed 063 Mesarosova, L FC05.4.5, Mon 219 Mesdaghinia, A Tue 231 Mesdaghinia, Eh Thu 209 Mesquita, C Mon 398 Messing, DD Thu 014 Messlinger, K Mon 099 Messripour, M Thu 004 Mester, G Thu 307 Mester, M W19.3 Methven, L W01.2.2, Thu 030 Metsvaht, T FC10.3.6 Metz, J Tue 462 Meurs, H Tue 242, Wed 095 Meyer zu Schwabedissen, H Tue 045, Tue 054 Meyer, J FC02.2.5 Meyer, JG Mon 071 Meyer-Lindenberg, As FC17.3.3 Meyers, T Thu 012 Meyers, TM Thu 016 Mezei, Zsofia Thu 307 Mezhapuke, R Wed 045 Mhadhebi, L Wed 316 Miantezila Basilua, J Tue 040 Miao, Chao-Yu Thu 210 Micaelo, N Tue 146 Micale, V Thu 396 Micali, S Thu 316 Miceli, N Thu 316 MIchael, M Tue 238, Thu 317 Michailov, MC Mon 479, Thu 211, Tue 214, Mon 245, Tue 099 Michaud, V Wed 123 Michel, Lisa Tue 232 Michelon, H FC02.2.6 Michiels, C Wed 245 Micograve, U Thu 419 Micon, S Mon 140, Mon 141 Miczek, K FC14.4.3 Miettinen, T Mon 215 Mifsud, J Thu 002 Miftah, A Mon 378 Miglio, G Tue 256, Thu 434 Mihovilovic, MD Mon 217 Mijatovic, S FC16.3.6 Mikelis, C Thu 232 Miki, N Wed 186 Mikkelsen, S FC13.5.5 Mikkonen, J Thu 223 Mikolajczak, PL Thu 174 Mikov, I Tue 148 Mikov, M Mon 115, Tue 148, Tue 149, Tue 454, Wed 321 Mikov, MM W34.4, Wed 435 Milan, Z Tue 151 Milanese, M Thu 400 Milani, L Wed 136 Milbradt, J Tue 214, Thu 354 Milijasevic, B Tue 148, Militaru, FC Mon 417, Mon 438, Tue 481 Miljkovic, D FC16.3.6 Millan, MJ Wed 072 Millard, R FC08.1.6 Mille, M Mon 217, Mon 218 Millet, C Thu 244, Thu 245 Millfors, P Thu 003 Milliken, P Thu 272 Millington, WR Wed 179 Mills, A Thu 272 Milne, RW Tue 066 Milovan, D Wed 193 Milovanovic, D Mon 039, Milovanovic, DR Wed 435 Milovanovic, M Mon 114 Milovanovic, S Thu 329, Tue 122 Milton, S Tue 233 Milusheva, E Mon 460 Minakuchi, K Wed 278 Miners, J Wed 124 Mingorance Gutiérrez, C Tue 118 Minnaar, EL Wed 399 Minnaard-Huiban, M Mon 212 Mino, Y Tue 491 Minorics, R Thu 308 Miokovic, M Wed 171 Miralles, Diana V Tue 163 Miranda, AL Thu 212 Mirecki-Garrido, M Tue 392 Miremont, G FC09.2.7 Miremont-Salamé, G Tue 092 Miri, M Tue 469 Miri, R Wed 376 Miri, Ramin Thu 309 Mirkhani, H Wed 376 Mirmohammad Sadeghi, H YI.07 Mironidou-Tzouveleki, M Mon 367, Thu 206, Mon 297, Tue 126 Miroševic, V Mon 048 Mirosevic-Skvrce, N Wed 112 Mirossay, A Thu 033 Mirossay, L Thu 033, Thu 216 Mirtsou, V Tue 246 Mirtsou-Fidani, V Mon 143 Mirza, M Tue 395 Mirzadegan, T Wed 093 Mirzaei, A Thu 313 Mirziashvili, M Wed 272, Tue 174 Mirzoyan, R Wed 248 Misaka, S Tue 144 Misawa, M Mon 303, Mon 304, Mon 272, Tue 259, Tue 234, Tue 265, Tue 287 Misbahuddin, M Tue 119 Misfeldt, M Wed 229 Mishina, M Thu 034 Misioreck, C Thu 237 Misle, A Wed 024 Mistchenko, AS Mon 128 Mistiran, AF Tue 408 Mita, M Mon 179, Wed 305 Mitani, Y Tue 492 Mitchell, C Tue 353, Mon 351 Mitchell, JA FC09.4.1, Thu 200, Thu 238, Thu 241
Name Paper ref. Name Paper ref. Mitchell, S FC13.2.6, Wed 125, Wed 126 Mitic, R Wed 436 Mitjavila Cors, M Thu 347 Mitrovic, D Wed 343 Mittal, DK Thu 310 Miura, Jun Wed 127 Miura, M Tue 144 Miwa, S Mon 399 Miwa, T Tue 162 Miyagawa, K Thu 397, Thu 423, Thu 422 Miyahara, T Tue 459 Miyakawa, M Wed 223 Miyake, F Wed 117 Miyashiro, C Tue 241 Miyata, T Thu 387 Miyauchi, S Wed 064 Miyazaki, I Wed 424, Wed 413 Miyazaki, T Wed 256, Thu 213 Mizobuchi, S Mon 303 Mizuguchi, H Tue 154 Mizuma, K Wed 186, Tue 477 Mizutani, H Wed 107 Moachon, L FC09.2.7 Moazen, F YI.07 Mobasher, MA Mon 085, Mon 088 Mobini, H FC14.5.2 Moch, S Mon 478, Tue 001 Mochizuki, Y Wed 128 Modaresi, M Thu 004 Modess, C Tue 041, Tue 045 Moerland, M Mon 316, Thu 214, Thu 215 Mogi, M Mon 439 Mohajeri, SA Mon 230 Mohamad, MA Tue 444 Mohamad, N Mon 107, Thu 181 Mohammadi, S Mon 044, Tue 164 Moharamzad, Y Thu 005, Thu 311 Mohr Drewes, A W12.5 Mohsin, SSJ Thu 312 Mohy El-Din, MM Tue 264 Moibenko, A FC06.1.6 Moilanan, E FC09.1.5, FC09.3.1, FC09.5.4, FC16.3.4, W21.5, Mon 302, Mon 328, Tue 278, Tue 235, Tue 239, Tue 247, Tue 283 Moilanen, L Tue 235 Moilanen, T W21.5, Tue 283, Tue 239 Mojic, M FC16.3.6 Mojzis, J Thu 033, Tue 423 Mojzis, Jan Thu 216 Mojzisova, G Tue 423, Thu 216 Mokhtari, F FC01.3.5 Mokoena, M Mon 412 Mokrane, H Thu 035 Mokrosinski, Thu 036 Molana, H Mon 036 Molden, E Tue 490, Wed 412 Molero, E FC04.4.6 Molina-Guarneros, JA Tue 431 Mollentze, W FC14.5.5 Møller, A Thu 405, Thu 404, FC17.1.2 Møller, LB Mon 089 Möller, M FC18.2.5 Møller, MU Mon 090 Møller, TC Thu 086 Møller, T Thu 037 Mollica, A Mon 105, Wed 434 Mollik, AH Tue 097, Tue 120 Molloy, M W06.3 Molnar, P FC16.2.6 Molnar, S Tue 099 Molyva, D Mon 300 Momma, T Tue 345 Momo, K Tue 315 Moncada, S PL01, FC09.3.5 Monge, A Thu 212 Monge, L Wed 224 Mönkkönen, J Mon 060 Monnier, C FC11.2.1 Monopoli, A Mon 281 Monsalvo, I Tue 420 Montagnani, M W08.4 Montaña, M Wed 046 Montanaro, N FC04.3.6 Montane Jaime, L Wed 129, Tue 347 Montastruc, JL Tue 104 Monteiro, EC Wed 130 Monteiro, F Wed 131 Monteiro, H Wed 131 Monteiro, HSA Wed 297 Monteiro, J Wed 131 Montó Guillot, FJ Tue 165 Monto, F Thu 048, Tue 163 Monuki, Y Mon 307 Moon, S-M, Mon 049, Mon 359 Moore, N W32.2, Mon 140, Tue 092 Moradi, N FC09.5.7 Moraes, MEA Thu 374 Morales, C Tue 016 Morales, L Wed 152 Moral-Sanz, J Tue 121, Wed 226, Thu 217, Thu 235 Morbidelli, L Wed 243 Morcillo, E Thu 437 Moreau, P Tue 429 Moreira, A-P Mon 314 Moreira, F FC17.5.5 Moreira, IS YI.10 Moreno, E Thu 235, Thu 217 Moreno, L Tue 121, Mon 374, Wed 226 Moreno, L Thu 217 Morgadinho, T Thu 193 Morgado, M Thu 218 Morgado, S Thu 218 Morgan, ET W06.1 Mori, A Wed 264 Mori, H FC16.4.6 Mori, M Tue 147 Mori, S Tue 272, Mon 035, Mon 329, Thu 275 Mori, T Thu 103 Moriguchi, S Thu 406 Morikawa, M Mon 307 Morin, C Mon 469 Morini, G Mon 381 Morishima, S Thu 046 Morishima, T Tue 122 Index 353
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor